Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
57
ENBI.CX Quote, Financials, Valuation and Earnings
Last price:
$0.10
Seasonality move
:
30.28%
Day range:
$0.10 - $0.10
52-week range:
$0.07 - $0.45
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.48x
P/B ratio:
3.56x
Volume:
--
Avg. volume:
5.7K
1-year change:
-37.5%
Market cap:
$1.4M
Revenue:
--
EPS (TTM):
-$0.03
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ENBI.CX
Entheon Biomedical Corp.
|
-- | -- | -- | -- | -- |
|
COOL.CX
Core One Labs, Inc.
|
-- | -- | -- | -- | -- |
|
CURE.X.CX
Biocure Technology
|
-- | -- | -- | -- | -- |
|
HEAL.CX
|
-- | -- | -- | -- | -- |
|
LOBE.CX
Lobe Sciences Ltd.
|
-- | -- | -- | -- | -- |
|
NSHS.CX
NanoSphere Health Sciences, Inc.
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ENBI.CX
Entheon Biomedical Corp.
|
$0.10 | -- | $1.4M | -- | $0.00 | 0% | 2.48x |
|
COOL.CX
Core One Labs, Inc.
|
$0.15 | -- | $6.8M | -- | $0.00 | 0% | 32.71x |
|
CURE.X.CX
Biocure Technology
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
HEAL.CX
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
LOBE.CX
Lobe Sciences Ltd.
|
$0.05 | -- | $9.7M | -- | $0.00 | 0% | -- |
|
NSHS.CX
NanoSphere Health Sciences, Inc.
|
$0.0200 | -- | $205.5K | 0.52x | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ENBI.CX
Entheon Biomedical Corp.
|
-- | 3.654 | -- | 20.77x |
|
COOL.CX
Core One Labs, Inc.
|
-- | 0.000 | -- | -- |
|
CURE.X.CX
Biocure Technology
|
-- | 0.000 | -- | -- |
|
HEAL.CX
|
-- | 0.000 | -- | -- |
|
LOBE.CX
Lobe Sciences Ltd.
|
40.99% | -3.518 | 19.05% | 2.85x |
|
NSHS.CX
NanoSphere Health Sciences, Inc.
|
-3.43% | 1.456 | 20.53% | 0.00x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ENBI.CX
Entheon Biomedical Corp.
|
-- | -$49.9K | -100.93% | -100.93% | -- | -$27.2K |
|
COOL.CX
Core One Labs, Inc.
|
-- | -- | -- | -- | -- | -- |
|
CURE.X.CX
Biocure Technology
|
-- | -- | -- | -- | -- | -- |
|
HEAL.CX
|
-- | -- | -- | -- | -- | -- |
|
LOBE.CX
Lobe Sciences Ltd.
|
-- | -$1.1M | -1117.27% | -- | -- | -$408.2K |
|
NSHS.CX
NanoSphere Health Sciences, Inc.
|
-- | -$72.1K | -- | -- | -- | -$92.1K |
Entheon Biomedical Corp. vs. Competitors
-
Which has Higher Returns ENBI.CX or COOL.CX?
Core One Labs, Inc. has a net margin of -- compared to Entheon Biomedical Corp.'s net margin of --. Entheon Biomedical Corp.'s return on equity of -100.93% beat Core One Labs, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ENBI.CXEntheon Biomedical Corp.-- -$0.00 $389K COOL.CXCore One Labs, Inc.-- -- -- -
What do Analysts Say About ENBI.CX or COOL.CX?
Entheon Biomedical Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Core One Labs, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Entheon Biomedical Corp. has higher upside potential than Core One Labs, Inc., analysts believe Entheon Biomedical Corp. is more attractive than Core One Labs, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ENBI.CXEntheon Biomedical Corp.0 0 0 COOL.CXCore One Labs, Inc.0 0 0 -
Is ENBI.CX or COOL.CX More Risky?
Entheon Biomedical Corp. has a beta of 1.560, which suggesting that the stock is 56.019% more volatile than S&P 500. In comparison Core One Labs, Inc. has a beta of 0.495, suggesting its less volatile than the S&P 500 by 50.458%.
-
Which is a Better Dividend Stock ENBI.CX or COOL.CX?
Entheon Biomedical Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Core One Labs, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Entheon Biomedical Corp. pays -- of its earnings as a dividend. Core One Labs, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ENBI.CX or COOL.CX?
Entheon Biomedical Corp. quarterly revenues are --, which are larger than Core One Labs, Inc. quarterly revenues of --. Entheon Biomedical Corp.'s net income of -$47.1K is higher than Core One Labs, Inc.'s net income of --. Notably, Entheon Biomedical Corp.'s price-to-earnings ratio is -- while Core One Labs, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Entheon Biomedical Corp. is 2.48x versus 32.71x for Core One Labs, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ENBI.CXEntheon Biomedical Corp.2.48x -- -- -$47.1K COOL.CXCore One Labs, Inc.32.71x -- -- --
-
Which has Higher Returns ENBI.CX or CURE.X.CX?
Biocure Technology has a net margin of -- compared to Entheon Biomedical Corp.'s net margin of --. Entheon Biomedical Corp.'s return on equity of -100.93% beat Biocure Technology's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ENBI.CXEntheon Biomedical Corp.-- -$0.00 $389K CURE.X.CXBiocure Technology-- -- -- -
What do Analysts Say About ENBI.CX or CURE.X.CX?
Entheon Biomedical Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Biocure Technology has an analysts' consensus of -- which suggests that it could fall by --. Given that Entheon Biomedical Corp. has higher upside potential than Biocure Technology, analysts believe Entheon Biomedical Corp. is more attractive than Biocure Technology.
Company Buy Ratings Hold Ratings Sell Ratings ENBI.CXEntheon Biomedical Corp.0 0 0 CURE.X.CXBiocure Technology0 0 0 -
Is ENBI.CX or CURE.X.CX More Risky?
Entheon Biomedical Corp. has a beta of 1.560, which suggesting that the stock is 56.019% more volatile than S&P 500. In comparison Biocure Technology has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock ENBI.CX or CURE.X.CX?
Entheon Biomedical Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biocure Technology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Entheon Biomedical Corp. pays -- of its earnings as a dividend. Biocure Technology pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ENBI.CX or CURE.X.CX?
Entheon Biomedical Corp. quarterly revenues are --, which are larger than Biocure Technology quarterly revenues of --. Entheon Biomedical Corp.'s net income of -$47.1K is higher than Biocure Technology's net income of --. Notably, Entheon Biomedical Corp.'s price-to-earnings ratio is -- while Biocure Technology's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Entheon Biomedical Corp. is 2.48x versus -- for Biocure Technology. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ENBI.CXEntheon Biomedical Corp.2.48x -- -- -$47.1K CURE.X.CXBiocure Technology-- -- -- --
-
Which has Higher Returns ENBI.CX or HEAL.CX?
has a net margin of -- compared to Entheon Biomedical Corp.'s net margin of --. Entheon Biomedical Corp.'s return on equity of -100.93% beat 's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ENBI.CXEntheon Biomedical Corp.-- -$0.00 $389K HEAL.CX-- -- -- -
What do Analysts Say About ENBI.CX or HEAL.CX?
Entheon Biomedical Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand has an analysts' consensus of -- which suggests that it could fall by --. Given that Entheon Biomedical Corp. has higher upside potential than , analysts believe Entheon Biomedical Corp. is more attractive than .
Company Buy Ratings Hold Ratings Sell Ratings ENBI.CXEntheon Biomedical Corp.0 0 0 HEAL.CX0 0 0 -
Is ENBI.CX or HEAL.CX More Risky?
Entheon Biomedical Corp. has a beta of 1.560, which suggesting that the stock is 56.019% more volatile than S&P 500. In comparison has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock ENBI.CX or HEAL.CX?
Entheon Biomedical Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Entheon Biomedical Corp. pays -- of its earnings as a dividend. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ENBI.CX or HEAL.CX?
Entheon Biomedical Corp. quarterly revenues are --, which are larger than quarterly revenues of --. Entheon Biomedical Corp.'s net income of -$47.1K is higher than 's net income of --. Notably, Entheon Biomedical Corp.'s price-to-earnings ratio is -- while 's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Entheon Biomedical Corp. is 2.48x versus -- for . Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ENBI.CXEntheon Biomedical Corp.2.48x -- -- -$47.1K HEAL.CX-- -- -- --
-
Which has Higher Returns ENBI.CX or LOBE.CX?
Lobe Sciences Ltd. has a net margin of -- compared to Entheon Biomedical Corp.'s net margin of --. Entheon Biomedical Corp.'s return on equity of -100.93% beat Lobe Sciences Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ENBI.CXEntheon Biomedical Corp.-- -$0.00 $389K LOBE.CXLobe Sciences Ltd.-- -$0.01 $5.9M -
What do Analysts Say About ENBI.CX or LOBE.CX?
Entheon Biomedical Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Lobe Sciences Ltd. has an analysts' consensus of -- which suggests that it could grow by 14192.33%. Given that Lobe Sciences Ltd. has higher upside potential than Entheon Biomedical Corp., analysts believe Lobe Sciences Ltd. is more attractive than Entheon Biomedical Corp..
Company Buy Ratings Hold Ratings Sell Ratings ENBI.CXEntheon Biomedical Corp.0 0 0 LOBE.CXLobe Sciences Ltd.0 0 0 -
Is ENBI.CX or LOBE.CX More Risky?
Entheon Biomedical Corp. has a beta of 1.560, which suggesting that the stock is 56.019% more volatile than S&P 500. In comparison Lobe Sciences Ltd. has a beta of 0.215, suggesting its less volatile than the S&P 500 by 78.507%.
-
Which is a Better Dividend Stock ENBI.CX or LOBE.CX?
Entheon Biomedical Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lobe Sciences Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Entheon Biomedical Corp. pays -- of its earnings as a dividend. Lobe Sciences Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ENBI.CX or LOBE.CX?
Entheon Biomedical Corp. quarterly revenues are --, which are smaller than Lobe Sciences Ltd. quarterly revenues of --. Entheon Biomedical Corp.'s net income of -$47.1K is higher than Lobe Sciences Ltd.'s net income of -$1.1M. Notably, Entheon Biomedical Corp.'s price-to-earnings ratio is -- while Lobe Sciences Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Entheon Biomedical Corp. is 2.48x versus -- for Lobe Sciences Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ENBI.CXEntheon Biomedical Corp.2.48x -- -- -$47.1K LOBE.CXLobe Sciences Ltd.-- -- -- -$1.1M
-
Which has Higher Returns ENBI.CX or NSHS.CX?
NanoSphere Health Sciences, Inc. has a net margin of -- compared to Entheon Biomedical Corp.'s net margin of --. Entheon Biomedical Corp.'s return on equity of -100.93% beat NanoSphere Health Sciences, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ENBI.CXEntheon Biomedical Corp.-- -$0.00 $389K NSHS.CXNanoSphere Health Sciences, Inc.-- -$0.00 -$1.8M -
What do Analysts Say About ENBI.CX or NSHS.CX?
Entheon Biomedical Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand NanoSphere Health Sciences, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Entheon Biomedical Corp. has higher upside potential than NanoSphere Health Sciences, Inc., analysts believe Entheon Biomedical Corp. is more attractive than NanoSphere Health Sciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ENBI.CXEntheon Biomedical Corp.0 0 0 NSHS.CXNanoSphere Health Sciences, Inc.0 0 0 -
Is ENBI.CX or NSHS.CX More Risky?
Entheon Biomedical Corp. has a beta of 1.560, which suggesting that the stock is 56.019% more volatile than S&P 500. In comparison NanoSphere Health Sciences, Inc. has a beta of 0.627, suggesting its less volatile than the S&P 500 by 37.292%.
-
Which is a Better Dividend Stock ENBI.CX or NSHS.CX?
Entheon Biomedical Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NanoSphere Health Sciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Entheon Biomedical Corp. pays -- of its earnings as a dividend. NanoSphere Health Sciences, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ENBI.CX or NSHS.CX?
Entheon Biomedical Corp. quarterly revenues are --, which are smaller than NanoSphere Health Sciences, Inc. quarterly revenues of --. Entheon Biomedical Corp.'s net income of -$47.1K is lower than NanoSphere Health Sciences, Inc.'s net income of -$13.1K. Notably, Entheon Biomedical Corp.'s price-to-earnings ratio is -- while NanoSphere Health Sciences, Inc.'s PE ratio is 0.52x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Entheon Biomedical Corp. is 2.48x versus -- for NanoSphere Health Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ENBI.CXEntheon Biomedical Corp.2.48x -- -- -$47.1K NSHS.CXNanoSphere Health Sciences, Inc.-- 0.52x -- -$13.1K
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
